GSK PLC GSK shares shed 2.40% to £13.41 Wednesday, on what proved to be an all-around positive trading session for the stock ...

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...

Shares of GSK PLC GSK inched down 0.69% to £13.74 Tuesday, on what proved to be an all-around poor trading session for the ...

Blenrep, in combination with other drugs, reduced the risk of death by 42% in patients with multiple myeloma whose first ...

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares closed yesterday at p1,341.00. Pick the ...

Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...

GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for ...

China's Zhifei will pay GSK about 2.3 billion pounds ($2.9 billion) for the exclusive rights to distribute GSK's shingles ...

GSK (GSK) reported a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in certain ...

TD Cowen analyst Steve Scala maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of $45.00. The ...

GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed ...